# A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)

> **NCT00092352** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 395 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** MK0966, rofecoxib
- **DRUG:** Comparator: celecoxib, placebo

## Key facts

- **NCT ID:** NCT00092352
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04-29
- **Primary completion:** 2003-12-01
- **Final completion:** 2003-12-01
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092352, "A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00092352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*